Enlivex Ltd. - Ordinary Shares (ENLV) analyst actions
Rating and price-target actions on ENLV in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ENLV overview →
5 measured ENLV analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis | Press release | +0.80% | +0.80% | |
| Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis | Press release | -3.50% | +0.70% | |
| Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis | Press release | -1.07% | +5.00% | |
| Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis | Press release | -0.97% | -2.91% | |
| Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis | Press release | -1.03% | -1.38% |
Keep exploring
More ENLV: earnings → · SEC filings → · ENLV overview →